APPLIED THERAPEUTICS INC. - COMMON STOCK

Applied Therapeutics Reports Second Quarter 2022 Financial Results

12 أغسطس 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference

28 يوليو 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

22 يونيو 2022 22:12:40 بحسب Nasdaq GlobeNewswire

Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants

22 يونيو 2022 16:10:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia

03 يونيو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics to Present at the UBS Global Healthcare Conference

19 مايو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics Reports First Quarter 2022 Financial Results

12 مايو 2022 06:59:25 بحسب Nasdaq GlobeNewswire

Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society

05 مايو 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders

04 أبريل 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics

16 مارس 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results

10 مارس 2022 07:30:01 بحسب Nasdaq GlobeNewswire

Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences

01 مارس 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Applied Therapeutics Supports 15th Annual Rare Disease Day

28 فبراير 2022 07:30:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

10 فبراير 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

03 يناير 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

16 ديسمبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism

18 نوفمبر 2021 07:00:02 بحسب Nasdaq GlobeNewswire

Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency

25 أكتوبر 2021 07:00:00 بحسب Nasdaq GlobeNewswire

Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids

18 أكتوبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire

Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids

09 سبتمبر 2021 07:00:01 بحسب Nasdaq GlobeNewswire